Yashma Patel

Assessment of Minimal Residual Disease in Standard-Risk AML.

Yashma Patel, Robert K Hills, Hassan Farah, 2016, The New England journal of medicine.

TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis

R. Hills, D. Linch, D. Bowen, 2009, Leukemia.

Pediatric multiple sclerosis

L. Krupp, Y. Patel, Vikram Bhise, 2009, Annals of Indian Academy of Neurology.

Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.

F. Lo‐Coco, R. Hills, R. Clark, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.

R. Hills, D. Linch, A. Goldstone, 2010, Blood.

The Impact of FLT3-ITD and NPM1 Mutational Status on the Outcome of ATRA Therapy in Patients with Non-APL AML: Results of the UK MRC AML12 Trial

R. Hills, D. Linch, M. Lazenby, 2008 .

Multiple white matter tract abnormalities underlie cognitive impairment in RRMS

Hui Jing Yu, Mirjana Maletic-Savatic, Mark E. Wagshul, 2012, NeuroImage.